Secures $200M Senior Secured Credit Facility from Hercules Capital
FDMT has more than doubled off its 52-week low of $3.68 on elevated volume (2.5× avg).
Summary
4D Molecular Therapeutics secured a senior secured term loan facility for up to $200 million from Hercules Capital, with an initial draw of $20 million, to fund its operations and pipeline development.
Key Events · Financing and Capital Events · FDMT
-
New Credit Facility Established
The company entered into a Loan and Security Agreement with Hercules Capital, Inc. for up to $200 million in senior secured term loans.
-
Initial Funding Received
An initial Tranche 1A Loan of $20 million was drawn on June 24, 2026.
-
Future Tranches Tied to Milestones
Additional tranches totaling $180 million are available, subject to company election, achievement of certain milestones, and Hercules Capital's discretion.
-
Maturity and Interest Rates
The facility matures on June 1, 2031, with interest rates based on the prime rate plus 2.00% to 2.50%, with minimums of 8.75% to 9.25%.
Analysis · FDMT · Life Sciences
4D Molecular Therapeutics has secured a substantial credit facility, providing up to $200 million in non-dilutive capital. This financing is critical for a clinical-stage biotech company like 4D Molecular Therapeutics, which has significant R&D expenses, as it extends the cash runway and supports ongoing development of its gene therapy pipeline, including the lead candidate 4D-150. While it introduces debt and associated covenants, it avoids immediate equity dilution, which is a positive for existing shareholders.
At the time of this filing, FDMT was trading at $11.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $606.4M. The 52-week trading range was $3.68 to $12.34. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.